Fadi Brimo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Fadi Brimo has a total of 358 co-authors. Here are the top co-authors by number of shared publications:
- Armen Aprikian
McGill University
9 shared publications Wassim Kassouf
Department of Surgery (Urology) McGill University Health Center Montreal Quebec Canada
9 shared publicationsManon Auger
Department of Pathology McGill University and McGill University Health Center Montreal Quebec Canada
7 shared publications- Simone Chevalier
Department of Surgery (Urology), McGill University and The Montreal General Hospital Research Institute, Montreal, Canada
7 shared publications - Wassim Kassouf
Department of Surgery, McGill University, Montreal, Quebec, Canada
7 shared publications Armen Aprikian
Department of Urology, McGill University Health Center, Montreal, Quebec H3G1A4, Canada
5 shared publications
Latest Publications
- 2 September 2026
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
International Society of Urological Pathology Multidisciplinary Expert Consultation Conference on Evaluation of Treatment Effects in Prostate and Bladder Cancer
Treatment effects in the urinary bladder are variable and range from localized post-transurethral resection changes to widespread systemic therapy effects. The International Society of Urological Pathology (ISUP) organized a consensus meeting in Vienna, Austria, in September 2025, focused on the evaluation of treatment effects in both the prostate and bladder. Working Group 2 was assigned the topic of the urinary bladder, and a group of pathologists and clinicians was convened. They worked cooperatively to develop a 30-question, premeeting survey for the ISUP membership, which covered the following topics: systemic therapy–related changes, intravesical therapy and radiotherapy-related changes, macroscopic examination and reporting of treated bladder specimens, and relevant ancillary testing methods for grossly residual and/or minimal residual disease. The premeeting survey results highlighted uncertainty about tumor regression grading (TRG), variability in reporting practices for post-resection and intravesical therapy cases, and divergent opinions on the potential utility of molecular testing. Based on findings from this crowd-sourced experience, the Working Group researched the primary medical literature to study the problematic premeeting survey topics, curated focused presentations of published experience for the consensus meeting participants and developed refined consensus questions for consensus voting. Consensus was achieved in 18/19 polling statements. Use of molecular tests to distinguish benign mimickers from carcinoma did not reach consensus. Overall, the surveys and in-person consensus voting supported standardized reporting practices and terminology for post-therapy cases, interdisciplinary development of a bladder TRG scheme, and the utility of select molecular and immunohistochemical testing in the post-treatment setting.
- 2 September 2026
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
International Society of Urological Pathology Multidisciplinary Expert Consultation Conference on Evaluation of Treatment Effects in Prostate and Bladder Cancer
Treatment effects in the urinary bladder are variable and range from localized post-transurethral resection changes to widespread systemic therapy effects. The International Society of Urological Pathology (ISUP) organized a consensus meeting in Vienna, Austria, in September 2025, focused on the evaluation of treatment effects in both the prostate and bladder. Working Group 2 was assigned the topic of the urinary bladder, and a group of pathologists and clinicians was convened. They worked cooperatively to develop a 30-question, premeeting survey for the ISUP membership, which covered the following topics: systemic therapy–related changes, intravesical therapy and radiotherapy-related changes, macroscopic examination and reporting of treated bladder specimens, and relevant ancillary testing methods for grossly residual and/or minimal residual disease. The premeeting survey results highlighted uncertainty about tumor regression grading (TRG), variability in reporting practices for post-resection and intravesical therapy cases, and divergent opinions on the potential utility of molecular testing. Based on findings from this crowd-sourced experience, the Working Group researched the primary medical literature to study the problematic premeeting survey topics, curated focused presentations of published experience for the consensus meeting participants and developed refined consensus questions for consensus voting. Consensus was achieved in 18/19 polling statements. Use of molecular tests to distinguish benign mimickers from carcinoma did not reach consensus. Overall, the surveys and in-person consensus voting supported standardized reporting practices and terminology for post-therapy cases, interdisciplinary development of a bladder TRG scheme, and the utility of select molecular and immunohistochemical testing in the post-treatment setting.
- 13 March 2026
- Published by SAGE Publications in International Journal of Surgical Pathology
- Vol. 34 (5) , 1303-1309
FLCN -Mutated Tumors in Smith-Magenis Syndrome: A Case Report of FLCN -Associated Pathogenesis
Birt-Hogg-Dubé syndrome and Smith-Magenis syndrome both involve the 17p11.2 chromosomal region, with FLCN germline pathogenic variants causing Birt-Hogg-Dubé syndrome and RAI1 deletions causing Smith-Magenis syndrome. When Smith-Magenis syndrome deletions extend to include FLCN , Birt-Hogg-Dubé syndrome-related manifestations may develop; however, such occurrences remain anecdotal, particularly with respect to renal tumors. We describe a 35-year-old man with Smith-Magenis syndrome who developed two right renal tumors, including one confirmed FLCN -mutated tumor. Histology revealed a mosaic admixture of oncocytic and chromophobe-like cells with patchy keratin 7 and KIT expression. Molecular analysis identified a germline 17p11.2 deletion encompassing FLCN and RAI1 , together with a somatic FLCN splice-donor mutation (c.1300+1G>A), consistent with biallelic FLCN inactivation. These findings support a shared pathogenic mechanism between Smith-Magenis syndrome and Birt-Hogg-Dubé syndrome, contributing to the existing literature on FLCN -associated renal neoplasia. Recognition of this overlap is important for clinical awareness and further supports renal surveillance in Smith-Magenis syndrome patients.
- 13 March 2026
- Published by SAGE Publications in International Journal of Surgical Pathology
- Vol. 34 (5) , 1303-1309
FLCN -Mutated Tumors in Smith-Magenis Syndrome: A Case Report of FLCN -Associated Pathogenesis
Birt-Hogg-Dubé syndrome and Smith-Magenis syndrome both involve the 17p11.2 chromosomal region, with FLCN germline pathogenic variants causing Birt-Hogg-Dubé syndrome and RAI1 deletions causing Smith-Magenis syndrome. When Smith-Magenis syndrome deletions extend to include FLCN , Birt-Hogg-Dubé syndrome-related manifestations may develop; however, such occurrences remain anecdotal, particularly with respect to renal tumors. We describe a 35-year-old man with Smith-Magenis syndrome who developed two right renal tumors, including one confirmed FLCN -mutated tumor. Histology revealed a mosaic admixture of oncocytic and chromophobe-like cells with patchy keratin 7 and KIT expression. Molecular analysis identified a germline 17p11.2 deletion encompassing FLCN and RAI1 , together with a somatic FLCN splice-donor mutation (c.1300+1G>A), consistent with biallelic FLCN inactivation. These findings support a shared pathogenic mechanism between Smith-Magenis syndrome and Birt-Hogg-Dubé syndrome, contributing to the existing literature on FLCN -associated renal neoplasia. Recognition of this overlap is important for clinical awareness and further supports renal surveillance in Smith-Magenis syndrome patients.
- Open Access
- 28 December 2025
- Published by Wiley in Histopathology
- Vol. 88 (7) , 1430-1442
A minor high‐grade component in non‐invasive papillary urothelial carcinoma is not associated with a more indolent behaviour
Aims: The latest WHO edition proposed using a cut‐off of ≥5% high‐grade component (%HGc) as a criterion to label non‐invasive papillary urothelial carcinomas as high‐grade (pTaHG). It also suggested that tumours with minor high‐grade component behave more indolently and are better labelled as mixed low‐ and high‐grade papillary carcinomas. Methods and Results: We investigated the prognostic value of %HGc along with other clinical and morphological parameters. 130 pTaHGs and 96 pTaLGs were included. 9% and 12% of pTaHGs had ≤5% and ≤10% HGc, respectively. Anaplasia was present in six cases (5%), necrosis in 18 cases (14%) and CIS in 5 cases (4%). On average, the highest mitotic count per 1 HPF was 2.4 (range = 0–18), and the mean number of mitoses per 10 HPF was 9 (range: 0–93). The mean tumour diameter was 2.1 cm. Tumour multifocality was observed in 32 cases (25%). Among the histological parameters, only mitotic activity showed a correlation with the %HGc ( P < 0.001). While recurrence was not significantly different between pTaLGs and pTaHGs (25% vs 35%; P = 0.09), stage progression was significantly different (0% vs 8%; P = 0.005). The two parameters that were associated with recurrence in pTaHGs were tumour multifocality and BCG therapy, while none was associated with progression. %HGc ≤5% and ≤ 10% did not correlate with lower rates of recurrence nor progression. Conclusions: Those findings suggest that pTaHGs with minor HGc do not exhibit more indolent behaviour and should not be approached similar to pTaLGs. [Correction added on 13 April 2026, after first online publication: This version changes the preceding sentence from “should be approached” to “should not be approached”.]
- 28 December 2025
- Published by Wiley in Histopathology
- Vol. 88 (7) , 1430-1442
Open AccessA minor high‐grade component in non‐invasive papillary urothelial carcinoma is not associated with a more indolent behaviour
Aims: The latest WHO edition proposed using a cut‐off of ≥5% high‐grade component (%HGc) as a criterion to label non‐invasive papillary urothelial carcinomas as high‐grade (pTaHG). It also suggested that tumours with minor high‐grade component behave more indolently and are better labelled as mixed low‐ and high‐grade papillary carcinomas. Methods and Results: We investigated the prognostic value of %HGc along with other clinical and morphological parameters. 130 pTaHGs and 96 pTaLGs were included. 9% and 12% of pTaHGs had ≤5% and ≤10% HGc, respectively. Anaplasia was present in six cases (5%), necrosis in 18 cases (14%) and CIS in 5 cases (4%). On average, the highest mitotic count per 1 HPF was 2.4 (range = 0–18), and the mean number of mitoses per 10 HPF was 9 (range: 0–93). The mean tumour diameter was 2.1 cm. Tumour multifocality was observed in 32 cases (25%). Among the histological parameters, only mitotic activity showed a correlation with the %HGc ( P < 0.001). While recurrence was not significantly different between pTaLGs and pTaHGs (25% vs 35%; P = 0.09), stage progression was significantly different (0% vs 8%; P = 0.005). The two parameters that were associated with recurrence in pTaHGs were tumour multifocality and BCG therapy, while none was associated with progression. %HGc ≤5% and ≤ 10% did not correlate with lower rates of recurrence nor progression. Conclusions: Those findings suggest that pTaHGs with minor HGc do not exhibit more indolent behaviour and should not be approached similar to pTaLGs. [Correction added on 13 April 2026, after first online publication: This version changes the preceding sentence from “should be approached” to “should not be approached”.]
- Open Access
Evaluating the Role of Liquid Biopsy to Detect Pathogenic Homologous Recombination Repair (HRR) Gene Alterations in Metastatic Prostate Cancer
Background: Metastatic prostate cancers frequently harbour pathogenic aberrations in Homologous Recombination Repair (HRR) genes that confer sensitivity to PARP inhibitors (PARPi). Therefore, accurate identification of all eligible patients is needed. The development of a circulating tumour DNA (ctDNA) testing alternative is promising as genomic testing of archived tissue leads to a failure rate of up to 30–40% in prostate cancer. Methods: This was a bi-institutional retrospective cohort study of patients with metastatic prostate cancer treated at the Jewish General Hospital or the McGill University Health Center, Montreal, Canada, between 2021 and 2023. Molecular data and treatment information were abstracted from a chart review. Chi-square, Fisher’s exact test, and Mann–Whitney tests were used to assess differences between groups. Results: We identified 484 metastatic prostate cancer patients. Somatic and germline testing for HRR was performed in 55.4% (n = 268) and 20% (n = 97) patients, respectively. Somatic testing was performed on tissue (n = 192, 71.6%) or ctDNA from liquid biopsies (n = 18, 6.7%) or both (n = 58, 21.7%). Pathogenic somatic HRR alterations were detected in 48 patients (17.9%). BRCA2 was the most frequent (n = 17), followed by ATM (n = 11), then CHEK2 (n = 5). Amongst patients with germline testing, 13/97 (13.4%) had pathogenic alterations predicted to lead to deficient HRR, mostly BRCA2 (n = 9), and three had detectable BRCA2 in tissue. Dual testing modality (tissue+ctDNA) significantly enhanced the detection rate of HRR alterations 19/58 (32.7%) vs. 29/210 (13.8%) for single testing modality (tissue or ctDNA), p = 0.008. The rate of inconclusive results was significantly lower in dual testing modality 0/58 (0%) vs. 25/210 in single testing modality (11.9%), p = 0.003. Amongst the 14 patients who had discordant results between liquid and tissue tests, HRR abnormalities were more frequently identified in ctDNA (n = 11) vs. tissue (n = 3). Patients who had HRR deficiency detected only in ctDNA had older tissue samples (median 5.6 years) compared to those who had deficient HRR detected only in tissue (median 0.2 years; p = 0.14). Conclusions: These data highlight a potential role in implementing liquid biopsy—especially in patients who only have older archival tissue available or failed tissue testing—to improve the detection rate of deficient HRR. Our ongoing prospective study will further validate whether the addition of liquid biopsy can identify more patients who are eligible to receive precision therapies by increasing the rate of detection of HRR deficiency compared to routine tissue testing alone.
Open AccessEvaluating the Role of Liquid Biopsy to Detect Pathogenic Homologous Recombination Repair (HRR) Gene Alterations in Metastatic Prostate Cancer
Background: Metastatic prostate cancers frequently harbour pathogenic aberrations in Homologous Recombination Repair (HRR) genes that confer sensitivity to PARP inhibitors (PARPi). Therefore, accurate identification of all eligible patients is needed. The development of a circulating tumour DNA (ctDNA) testing alternative is promising as genomic testing of archived tissue leads to a failure rate of up to 30–40% in prostate cancer. Methods: This was a bi-institutional retrospective cohort study of patients with metastatic prostate cancer treated at the Jewish General Hospital or the McGill University Health Center, Montreal, Canada, between 2021 and 2023. Molecular data and treatment information were abstracted from a chart review. Chi-square, Fisher’s exact test, and Mann–Whitney tests were used to assess differences between groups. Results: We identified 484 metastatic prostate cancer patients. Somatic and germline testing for HRR was performed in 55.4% (n = 268) and 20% (n = 97) patients, respectively. Somatic testing was performed on tissue (n = 192, 71.6%) or ctDNA from liquid biopsies (n = 18, 6.7%) or both (n = 58, 21.7%). Pathogenic somatic HRR alterations were detected in 48 patients (17.9%). BRCA2 was the most frequent (n = 17), followed by ATM (n = 11), then CHEK2 (n = 5). Amongst patients with germline testing, 13/97 (13.4%) had pathogenic alterations predicted to lead to deficient HRR, mostly BRCA2 (n = 9), and three had detectable BRCA2 in tissue. Dual testing modality (tissue+ctDNA) significantly enhanced the detection rate of HRR alterations 19/58 (32.7%) vs. 29/210 (13.8%) for single testing modality (tissue or ctDNA), p = 0.008. The rate of inconclusive results was significantly lower in dual testing modality 0/58 (0%) vs. 25/210 in single testing modality (11.9%), p = 0.003. Amongst the 14 patients who had discordant results between liquid and tissue tests, HRR abnormalities were more frequently identified in ctDNA (n = 11) vs. tissue (n = 3). Patients who had HRR deficiency detected only in ctDNA had older tissue samples (median 5.6 years) compared to those who had deficient HRR detected only in tissue (median 0.2 years; p = 0.14). Conclusions: These data highlight a potential role in implementing liquid biopsy—especially in patients who only have older archival tissue available or failed tissue testing—to improve the detection rate of deficient HRR. Our ongoing prospective study will further validate whether the addition of liquid biopsy can identify more patients who are eligible to receive precision therapies by increasing the rate of detection of HRR deficiency compared to routine tissue testing alone.
- Open Access
- 18 June 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (12) , 5839
Refined Procedure to Purify and Sequence Circulating Cell-Free DNA in Prostate Cancer
Cell-free DNA (cfDNA), a fragmented DNA circulating in blood, is a promising biomarker for cancer diagnosis and monitoring. Standardization of cfDNA isolation to enhance the sensitivity of molecular analyses in prostate cancer (PCa) is required. Towards this goal, we optimized existing methods to obtain a high quantity and quality of cfDNA from low volumes of plasma. The protocol was applied to samples from healthy males and three patient categories: radical prostatectomy (RP), disease-free (>6 years post-RP), and metastatic castration-resistant PCa (mCRPC). The yield was significantly higher in mCRPC cases, and the size of fragments was shorter. We compared for the first time library preparation using two cfDNA inputs and low vs. high sequencing depth. Clonal events were observed irrespective of input and depth, but lower input showed more subclonal events. The clinical application of the refined protocols to cfDNA samples from an mCRPC patient showed no tumor fraction before RP, while it increased to 25% at the advanced stage. Among chromosomal changes and mutations, the androgen receptor gene amplification was detected. Altogether, this comprehensive study on improved cfDNA procedures is highly promising to enhance the quality of liquid biopsy-based research for discoveries and much-needed clinical applications.
- 18 June 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (12) , 5839
Open AccessRefined Procedure to Purify and Sequence Circulating Cell-Free DNA in Prostate Cancer
Cell-free DNA (cfDNA), a fragmented DNA circulating in blood, is a promising biomarker for cancer diagnosis and monitoring. Standardization of cfDNA isolation to enhance the sensitivity of molecular analyses in prostate cancer (PCa) is required. Towards this goal, we optimized existing methods to obtain a high quantity and quality of cfDNA from low volumes of plasma. The protocol was applied to samples from healthy males and three patient categories: radical prostatectomy (RP), disease-free (>6 years post-RP), and metastatic castration-resistant PCa (mCRPC). The yield was significantly higher in mCRPC cases, and the size of fragments was shorter. We compared for the first time library preparation using two cfDNA inputs and low vs. high sequencing depth. Clonal events were observed irrespective of input and depth, but lower input showed more subclonal events. The clinical application of the refined protocols to cfDNA samples from an mCRPC patient showed no tumor fraction before RP, while it increased to 25% at the advanced stage. Among chromosomal changes and mutations, the androgen receptor gene amplification was detected. Altogether, this comprehensive study on improved cfDNA procedures is highly promising to enhance the quality of liquid biopsy-based research for discoveries and much-needed clinical applications.
- Open Access
- 9 June 2025
- Published by Wiley in Diagnostic Cytopathology
- Vol. 53 (9) , 447-453
The Spectrum of Polyoma Virus and Polyoma Virus‐Like Changes in Urine Cytology: When Should an Atypical Diagnosis Be Considered
Background: While the Paris system for reporting urinary cytology states that cells with well‐recognized and typical changes of polyoma virus (PV) infection should not lead to a diagnosis of ‘atypia, the prognostic significance of PV‐like features is unknown.Methods: Included were 284 urine cytology cases with PV or PV‐like changes. Four cell types were identified. Cell A was typical of PV infection, cell B had a spider‐web chromatin pattern, and cells C and D were degenerated cells with clumpy chromatin or homogeneous severely hyperchromatic nuclei, respectively. Events were correlated with a subsequent histological diagnosis of high‐grade urothelial carcinoma (HGUC).Results: 47% of cases had more than one cell type. The most common cell was D (64%) and the least common was A (27%). The most common cell to be present in isolation was D (n = 109, 60%). 92% of cases with cell A had other cell types. Overall, the presence of cell A was associated with a benign follow‐up (1.2% association with HGUC). There was a gradual increase in the association with a HGUC diagnosis in cases with cells B (PPV = 8%), C (PPV = 15.5%), and D (PPV = 44%). The presence of only cells B, C, or D was predictive of HGUC in 22.4%, 33.3%, and 61.5%, respectively.Conclusions: Cases with cell type A can be confidently diagnosed as ‘negative for HGUC’, even in the presence of associated cells with PV‐like changes. Cases with cells displaying PV‐like features (cell type B, C, or D) in the absence of type A features may represent degenerated HGUC cells.
- 9 June 2025
- Published by Wiley in Diagnostic Cytopathology
- Vol. 53 (9) , 447-453
Open AccessThe Spectrum of Polyoma Virus and Polyoma Virus‐Like Changes in Urine Cytology: When Should an Atypical Diagnosis Be Considered
Background: While the Paris system for reporting urinary cytology states that cells with well‐recognized and typical changes of polyoma virus (PV) infection should not lead to a diagnosis of ‘atypia, the prognostic significance of PV‐like features is unknown.Methods: Included were 284 urine cytology cases with PV or PV‐like changes. Four cell types were identified. Cell A was typical of PV infection, cell B had a spider‐web chromatin pattern, and cells C and D were degenerated cells with clumpy chromatin or homogeneous severely hyperchromatic nuclei, respectively. Events were correlated with a subsequent histological diagnosis of high‐grade urothelial carcinoma (HGUC).Results: 47% of cases had more than one cell type. The most common cell was D (64%) and the least common was A (27%). The most common cell to be present in isolation was D (n = 109, 60%). 92% of cases with cell A had other cell types. Overall, the presence of cell A was associated with a benign follow‐up (1.2% association with HGUC). There was a gradual increase in the association with a HGUC diagnosis in cases with cells B (PPV = 8%), C (PPV = 15.5%), and D (PPV = 44%). The presence of only cells B, C, or D was predictive of HGUC in 22.4%, 33.3%, and 61.5%, respectively.Conclusions: Cases with cell type A can be confidently diagnosed as ‘negative for HGUC’, even in the presence of associated cells with PV‐like changes. Cases with cells displaying PV‐like features (cell type B, C, or D) in the absence of type A features may represent degenerated HGUC cells.
- Open Access
- 13 May 2025
- Published by Wiley in Histopathology
- Vol. 87 (2) , 206-222
Current practices in prostate pathology reporting: results from a survey of genitourinary and general pathologists
Aims: Standardizing pathology reporting protocols through peer consensus review is critical for the best quality of care metrics. Reporting heterogeneity due to discrepancies among professional societies and practice patterns may lead to heterogeneous management and treatment approaches. This issue prompted a multi‐institutional survey of pathologists to address potential similarities or differences in trends and practice patterns in prostate pathology reporting worldwide.Methods and Results: A REDCap survey was distributed among 175 pathologists worldwide, recruited through invitations and social media. The response rate among invited pathologists was 83%. The practice locations were as follows: North America (USA, Canada, and Mexico, 62%), Europe (17%), Australia/New Zealand (3%), Central/South America (2%), Asia (13%), and Africa (2%). Most pathologists practiced for <5 years (28%). A genitourinary (GU) pathology fellowship was completed by 37%, 58% practiced in a subspecialized setting, and 43% in academia. Reporting includes (63%) or subtracts (37%) intervening benign tissue. Both Gleason score and Grade Groups (GG)s were reported by 96% of responders, whereas 94% report percent pattern 4 (%4). Aggregate grading and volume estimation in undesignated cores with different grades in the same jar are reported by 73% and 54% for systematic biopsies, and 83% and 62% for targeted biopsies, respectively. Cribriform morphology was reported by 81%. For presumed intraductal carcinoma (IDC), 89% use basal cell markers when isolated (iIDC), 82% with GG1 cancer, and 37% with ≥GG2. iIDC or IDC associated with GG1 or with ≥GG2 was not graded by 90%, 78%, and 70%, respectively. In radical prostatectomies, 90% report %4, but only 53% report it if the overall grade is ≥7. A tumour with Gleason 3 + 3 = 6 and <5% pattern 4 was graded as GG2 by 64%. A 5% pattern 4 or 5 as a secondary pattern. Grading was assigned based on the dominant nodule by 59%. Finally, reporting practices were significantly associated with demographic characteristics.Conclusions: Although most issues are agreed upon, significant discordance is identified among societies and pathologists in different practice settings. We hope this survey will serve as the basis for future studies and new collaborative approaches to more standardized reporting practices.
- 13 May 2025
- Published by Wiley in Histopathology
- Vol. 87 (2) , 206-222
Open AccessCurrent practices in prostate pathology reporting: results from a survey of genitourinary and general pathologists
Aims: Standardizing pathology reporting protocols through peer consensus review is critical for the best quality of care metrics. Reporting heterogeneity due to discrepancies among professional societies and practice patterns may lead to heterogeneous management and treatment approaches. This issue prompted a multi‐institutional survey of pathologists to address potential similarities or differences in trends and practice patterns in prostate pathology reporting worldwide.Methods and Results: A REDCap survey was distributed among 175 pathologists worldwide, recruited through invitations and social media. The response rate among invited pathologists was 83%. The practice locations were as follows: North America (USA, Canada, and Mexico, 62%), Europe (17%), Australia/New Zealand (3%), Central/South America (2%), Asia (13%), and Africa (2%). Most pathologists practiced for <5 years (28%). A genitourinary (GU) pathology fellowship was completed by 37%, 58% practiced in a subspecialized setting, and 43% in academia. Reporting includes (63%) or subtracts (37%) intervening benign tissue. Both Gleason score and Grade Groups (GG)s were reported by 96% of responders, whereas 94% report percent pattern 4 (%4). Aggregate grading and volume estimation in undesignated cores with different grades in the same jar are reported by 73% and 54% for systematic biopsies, and 83% and 62% for targeted biopsies, respectively. Cribriform morphology was reported by 81%. For presumed intraductal carcinoma (IDC), 89% use basal cell markers when isolated (iIDC), 82% with GG1 cancer, and 37% with ≥GG2. iIDC or IDC associated with GG1 or with ≥GG2 was not graded by 90%, 78%, and 70%, respectively. In radical prostatectomies, 90% report %4, but only 53% report it if the overall grade is ≥7. A tumour with Gleason 3 + 3 = 6 and <5% pattern 4 was graded as GG2 by 64%. A 5% pattern 4 or 5 as a secondary pattern. Grading was assigned based on the dominant nodule by 59%. Finally, reporting practices were significantly associated with demographic characteristics.Conclusions: Although most issues are agreed upon, significant discordance is identified among societies and pathologists in different practice settings. We hope this survey will serve as the basis for future studies and new collaborative approaches to more standardized reporting practices.
- Open Access
- 10 April 2024
- Published by Elsevier in Human Pathology
- Vol. 146, 66-74
Long term evaluation of optimized Gleason grading in a large cohort of men with prostate cancer in Canada
- 10 April 2024
- Published by Elsevier in Human Pathology
- Vol. 146, 66-74
Open AccessLong term evaluation of optimized Gleason grading in a large cohort of men with prostate cancer in Canada
- Open Access
- 7 September 2023
- Published by Wiley in Histopathology
- Vol. 83 (6) , 949-958
ABCC2 brush‐border expression predicts outcome in papillary renal cell carcinoma: a multi‐institutional study of 254 cases
Aims: Papillary renal cell carcinoma (PRCC) histologic subtyping is no longer recommended in the 2022 WHO classification. Currently, WHO/ISUP nucleolar grade is the only accepted prognostic histologic parameter for PRCC. ABCC2, a renal drug transporter, has been shown to significantly predict outcomes in PRCC. In this study we evaluated the prognostic significance of ABCC2 IHC staining patterns in a large, mult-iinstitutional PRCC cohort and assessed the association of these patterns with ABCC2 mRNA expression. Methods and results: We assessed 254 PRCCs for ABCC2 IHC reactivity patterns that were stratified into negative, cytoplasmic, brush-border = 50%. RNA in situ hybridization (ISH) was used to determine the transcript level of each group. Survival analysis was performed with SPSS and GraphPad software. RNA-ISH showed that the ABCC2 group with any brush-border staining was associated with a significant increase in the transcript level, when compared to the negative/cytoplasmic group (P = 0.034). Both ABCC2 groups with brush-border = 50% (P < 0.001) were also associated with worse disease-free survival (DFS) in univariate analysis. Multivariate analysis showed that only ABCC2 IHC brush-border (= 50%) reactivity groups (P = 0.037 and P = 0.003, respectively), and highstage disease (P < 0.001) had a DFS of prognostic significance. In addition, ABCC2 brush-border showed significantly worse DFS in pT1a (P = 0.014), pT1 (P = 0.013), <= 4 cmtumour (P = 0.041) and high stage (P = 0.014) groups, while a similar analysis with high WHO/ISUP grade in these groups was not significant. Conclusion: ABCC2 IHC brush-border expression in PRCC correlates with significantly higher gene expression and also independently predicts survival outcomes.
- 7 September 2023
- Published by Wiley in Histopathology
- Vol. 83 (6) , 949-958
Open AccessABCC2 brush‐border expression predicts outcome in papillary renal cell carcinoma: a multi‐institutional study of 254 cases
Aims: Papillary renal cell carcinoma (PRCC) histologic subtyping is no longer recommended in the 2022 WHO classification. Currently, WHO/ISUP nucleolar grade is the only accepted prognostic histologic parameter for PRCC. ABCC2, a renal drug transporter, has been shown to significantly predict outcomes in PRCC. In this study we evaluated the prognostic significance of ABCC2 IHC staining patterns in a large, mult-iinstitutional PRCC cohort and assessed the association of these patterns with ABCC2 mRNA expression. Methods and results: We assessed 254 PRCCs for ABCC2 IHC reactivity patterns that were stratified into negative, cytoplasmic, brush-border = 50%. RNA in situ hybridization (ISH) was used to determine the transcript level of each group. Survival analysis was performed with SPSS and GraphPad software. RNA-ISH showed that the ABCC2 group with any brush-border staining was associated with a significant increase in the transcript level, when compared to the negative/cytoplasmic group (P = 0.034). Both ABCC2 groups with brush-border = 50% (P < 0.001) were also associated with worse disease-free survival (DFS) in univariate analysis. Multivariate analysis showed that only ABCC2 IHC brush-border (= 50%) reactivity groups (P = 0.037 and P = 0.003, respectively), and highstage disease (P < 0.001) had a DFS of prognostic significance. In addition, ABCC2 brush-border showed significantly worse DFS in pT1a (P = 0.014), pT1 (P = 0.013), <= 4 cmtumour (P = 0.041) and high stage (P = 0.014) groups, while a similar analysis with high WHO/ISUP grade in these groups was not significant. Conclusion: ABCC2 IHC brush-border expression in PRCC correlates with significantly higher gene expression and also independently predicts survival outcomes.
- Open Access
- 1 August 2023
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 210 (2) , 257-271
Multimodal Biomarkers That Predict the Presence of Gleason Pattern 4: Potential Impact for Active Surveillance
Latent grade group ≥2 prostate cancer can impact the performance of active surveillance protocols. To date, molecular biomarkers for active surveillance have relied solely on RNA or protein. We trained and independently validated multimodal (mRNA abundance, DNA methylation, and/or DNA copy number) biomarkers that more accurately separate grade group 1 from grade group ≥2 cancers. Low- and intermediate-risk prostate cancer patients were assigned to training (n=333) and validation (n=202) cohorts. We profiled the abundance of 342 mRNAs, 100 DNA copy number alteration loci, and 14 hypermethylation sites at 2 locations per tumor. Using the training cohort with cross-validation, we evaluated methods for training classifiers of pathological grade group ≥2 in centrally reviewed radical prostatectomies. We trained 2 distinct classifiers, PRONTO-e and PRONTO-m, and validated them in an independent radical prostatectomy cohort. PRONTO-e comprises 353 mRNA and copy number alteration features. PRONTO-m includes 94 clinical, mRNAs, copy number alterations, and methylation features at 14 and 12 loci, respectively. In independent validation, PRONTO-e and PRONTO-m predicted grade group ≥2 with respective true-positive rates of 0.81 and 0.76, and false-positive rates of 0.43 and 0.26. Both classifiers were resistant to sampling error and identified more upgrading cases than a well-validated presurgical risk calculator, CAPRA (Cancer of the Prostate Risk Assessment; P < .001). Two grade group classifiers with superior accuracy were developed by incorporating RNA and DNA features and validated in an independent cohort. Upon further validation in biopsy samples, classifiers with these performance characteristics could refine selection of men for active surveillance, extending their treatment-free survival and intervals between surveillance.
- 1 August 2023
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 210 (2) , 257-271
Open AccessMultimodal Biomarkers That Predict the Presence of Gleason Pattern 4: Potential Impact for Active Surveillance
Latent grade group ≥2 prostate cancer can impact the performance of active surveillance protocols. To date, molecular biomarkers for active surveillance have relied solely on RNA or protein. We trained and independently validated multimodal (mRNA abundance, DNA methylation, and/or DNA copy number) biomarkers that more accurately separate grade group 1 from grade group ≥2 cancers. Low- and intermediate-risk prostate cancer patients were assigned to training (n=333) and validation (n=202) cohorts. We profiled the abundance of 342 mRNAs, 100 DNA copy number alteration loci, and 14 hypermethylation sites at 2 locations per tumor. Using the training cohort with cross-validation, we evaluated methods for training classifiers of pathological grade group ≥2 in centrally reviewed radical prostatectomies. We trained 2 distinct classifiers, PRONTO-e and PRONTO-m, and validated them in an independent radical prostatectomy cohort. PRONTO-e comprises 353 mRNA and copy number alteration features. PRONTO-m includes 94 clinical, mRNAs, copy number alterations, and methylation features at 14 and 12 loci, respectively. In independent validation, PRONTO-e and PRONTO-m predicted grade group ≥2 with respective true-positive rates of 0.81 and 0.76, and false-positive rates of 0.43 and 0.26. Both classifiers were resistant to sampling error and identified more upgrading cases than a well-validated presurgical risk calculator, CAPRA (Cancer of the Prostate Risk Assessment; P < .001). Two grade group classifiers with superior accuracy were developed by incorporating RNA and DNA features and validated in an independent cohort. Upon further validation in biopsy samples, classifiers with these performance characteristics could refine selection of men for active surveillance, extending their treatment-free survival and intervals between surveillance.